Vizora日本語

Morishita JintanMORISHITA JINTAN CO.,LTD.4524東証スタンダード医薬品FY ending Mar 2026, consolidated, J-GAAP

Morishita Jintan FY ending Mar 2020 results

About 75% of Morishita Jintan's sales come from Healthcare business division, with Capsule contract manufacturing business division and Other making up much of the rest.

Out of every ¥100 of sales, about ¥5 is left as operating profit.

Where the money goes

Where ¥100 of sales goes

For every ¥100 Morishita Jintan sells, how much goes where, and how much is kept.

FY ending Mar 2020
Cost of sales
¥47
SG&A
¥48
Operating profit
¥5
Net profit kept
¥3

Margin funnel (derived from reported values)Gross margin 53.0% → Operating margin 4.6% → Net margin 3.3%

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2020
  • Healthcare business division¥7.3B
    75%
    Op. margin 5.0%
  • Capsule contract manufacturing business division¥2.39B
    24%
    Op. margin -0.3%
  • Other¥74M
    1%
    Op. margin 128.4%

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (3)

  • EDINET (FSA Japan)

    有価証券報告書－第87期(2023/04/01－2024/03/31)

    ID S100TRZ72024-06-26Open

  • EDINET (FSA Japan)

    有価証券報告書－第85期(令和3年4月1日－令和4年3月31日)

    ID S100OJ6V2022-06-29Open

  • EDINET (FSA Japan)

    有価証券報告書－第84期(令和2年4月1日－令和3年3月31日)

    ID S100LOVX2021-06-29Open

Extracted from XBRL: 44 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image